Is Arbutus Biopharma Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 3 Wall Street analysts covering (NASDAQ: ABUS) stock is to Strong Buy ABUS stock.
Out of 3 analysts, 1 (33.33%) are recommending ABUS as a Strong Buy, 2 (66.67%) are recommending ABUS as a Buy, 0 (0%) are recommending ABUS as a Hold, 0 (0%) are recommending ABUS as a Sell, and 0 (0%) are recommending ABUS as a Strong Sell.
What is ABUS's forecast return on equity (ROE) for 2023-2026?
(NASDAQ: ABUS) forecast ROE is N/A, which is considered weak.
What is ABUS's Price Target?
According to 3 Wall Street analysts that have issued a 1 year ABUS price target, the average ABUS price target is $6.00, with the highest ABUS stock price forecast at $6.00 and the lowest ABUS stock price forecast at $6.00.
On average, Wall Street analysts predict that Arbutus Biopharma's share price could reach $6.00 by Sep 12, 2024. The average Arbutus Biopharma stock price prediction forecasts a potential upside of 212.5% from the current ABUS share price of $1.92.
What is ABUS's forecast return on assets (ROA) for 2023-2026?
(NASDAQ: ABUS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.05%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.